Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study

EuroIntervention 2018;13:2003-2011 published online January 2018. DOI: 10.4244/EIJ-D-17-00672

Martin Bergmann
Martin W. Bergmann1*, MD, PhD, FESC; Hüseyin Ince2, MD; Stephan Kische3, MD; Thomas Schmitz4, MD; Felix Meincke5, MD; Boris Schmidt6, MD; David Foley7, MB, BCh, PhD; Timothy R. Betts8, MD; Marek Grygier9, MD; Alexey V. Protopopov10, MD; Kenneth M. Stein11, MD; Lucas V.A. Boersma12, MD
1. Cardiologicum Hamburg, Hamburg, Germany; 2. Abt. Kardiologie, Vivantes Klinikum Am Urban, Berlin, Germany; 3. Abt. Kardiologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 4. Abt. Kardiologie, Elisabeth Krankenhaus, Essen, Germany; 5. Abt. Ka

Aims: The study aimed to confirm the efficacy and safety of WATCHMAN LAA closure in atrial fibrillation patients unsuitable for oral anticoagulation.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

atrial fibrillationischaemic strokelaa closure
Interventions for strokeLAA closure
Read next article
Alcohol septal ablation preceding transcatheter valve implantation to prevent left ventricular outflow tract obstruction

Latest news